| vaccine_type=
| mab_type=
| _number_of_combo_chemicals=Script error: No such module "ParameterCount".
| _vaccine_data=
| _mab_data=
| _mab_vaccine_data=
| _mab_other_data=21302CCCCCc1cc(c2c(c1)OC([C@H]3[C@H]2C=C(CC3)C)(C)C)O−152° (ethanol)1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1CYQFCXCEBYINGO-IAGOWNOFSA-NTemplate:StdinchiciteTemplate:Stdinchicite155–1570.0028
| _combo_data=
| _physiological_data=
| _clinical_data=Relatively low: 9%Script error: No such module "Unsubst".Physical: Low Psychological: Low–moderateDronabinol
By mouth, transdermal, sublingual, inhalationMarinol, SyndrosCannabinoidA04
| _legal_data=Unscheduled: ACT, Schedule 8 (Controlled Drug)[1]Dronabinol: A3; THC <30mg/ml: A3; others: F2 (prohibited).Unscheduled(Does not apply to THC as part of cannabis, which is regulated separately, see Cannabis (drug))Dronabinol: Anlage III, Δ9-THC: II, other isomers and their stereochemical variants: I.Class B (medicine form)Class B/IIP ISchedule II as Syndros, Schedule III as Marinol,[2]Schedule I as Δ9-THC in pure formIn general Rx-only
| _countSecondIDs=Script error: No such module "ParameterCount".
| _countIndexlabels=Script error: No such module "ParameterCount".
| _trackListSortletter=
|QID =
|QID2 =
|Verifiedfields=changed
|Watchedfields=changed
|verifiedrevid=420242758}}
Tetrahydrocannabinol (THC) is a cannabinoid found in cannabis.[3] It is the principal psychoactive constituent of Cannabis and one of at least 113 total cannabinoids identified on the plant. Although the chemical formula for THC (C21H30O2) describes multiple isomers,[4] the term THC usually refers to the delta-9-THC isomer with chemical name (−)-trans-Δ9-tetrahydrocannabinol. It is a colorless oil.
THC can be administered orally, inhaled, or transdermally, with bioavailability and onset varying by route, and is extensively metabolized in the liver to active and inactive metabolites before being excreted in feces and urine. Side effects include red eyes, dry mouth, drowsiness, memory impairment, anxiety, and, with chronic use, cannabinoid hyperemesis syndrome. While human overdose is rare, THC can interact with other drugs and has a complex pharmacokinetic profile.
THC is classified variably under international and US law, with medical use approved in multiple countries. Research supports its effectiveness for spasticity, central pain, and some multiple sclerosis symptoms, though evidence for other neurological disorders is limited, and long-term high-dose exposure may carry uncertain toxicity risks.
Chronic usage of THC may result in cannabinoid hyperemesis syndrome (CHS), a condition characterized by cyclic nausea, vomiting, and abdominal pain that may persist for months to years after discontinuation.[10]
Overdose
The median lethal dose of THC in humans is not fully known as there is conflicting evidence. A 1972 study gave up to 90 mg/kg of THC to dogs and monkeys without any lethal effects. Some rats died within 72 hours after a dose of up to 36 mg/kg.[12] A 2014 case study based on the toxicology reports and relative testimony in two separate cases gave the median lethal dose in humans at 30 mg/kg (2.1 grams THC for a person who weighs 70 kg; 154 lb; 11 stone), observing cardiovascular death in the one otherwise healthy subject of the two cases studied.[13] A different 1972 study gave the median lethal dose for intravenous THC in mice and rats at 30–40 mg/kg.[14] A 2020 fact sheet published by the US Drug Enforcement Administration stated that "[n]o deaths from overdose of marijuana have been reported."[15]
Script error: No such module "Labelled list hatnote".
Mechanism of action
Script error: No such module "For".
The actions of Δ9-THC result from its partial agonist activity at the cannabinoid receptorCB1 (Ki = 40.7 nM[18]), located mainly in the central nervous system, and the CB2 receptor (Ki = 36 nM[18]), mainly expressed in cells of the immune system.[19] The psychoactive effects of THC are primarily mediated by the activation of (mostly G-coupled) cannabinoid receptors, which result in a decrease in the concentration of the second messenger molecule cAMP through inhibition of adenylate cyclase.[20] The presence of these specialized cannabinoid receptors in the brain led researchers to the discovery of endocannabinoids, such as anandamide and 2-arachidonoyl glyceride (2-AG).Script error: No such module "Unsubst".
THC is a lipophilic molecule[21] and may bind non-specifically to a variety of entities in the brain and body, such as adipose tissue (fat).[22][23] THC, as well as other cannabinoids that contain a phenol group, possess mild antioxidant activity sufficient to protect neurons against oxidative stress, such as that produced by glutamate-induced excitotoxicity.[19]
THC targets receptors in a manner far less selective than endocannabinoid molecules released during retrograde signaling, as the drug has a relatively low cannabinoid receptor affinity. THC is also limited in its efficacy compared to other cannabinoids due to its partial agonistic activity, as THC appears to result in greater downregulation of cannabinoid receptors than endocannabinoids. Furthermore, in populations of low cannabinoid receptor density, THC may even act to antagonize endogenous agonists that possess greater receptor efficacy. However while THC's pharmacodynamic tolerance may limit the maximal effects of certain drugs, evidence suggests that this tolerance mitigates undesirable effects, thus enhancing the drug's therapeutic window.[24]
Recently, it has been shown that THC is also a partial autotaxin inhibitor, with an apparent IC50 of 407 ± 67 nM for the ATX-gamma isoform.[25] THC was also co-crystallized with autotaxin, deciphering the binding interface of the complex. These results might explain some of the effects of THC on inflammation and neurological diseases, since autotaxin is responsible of LPA generation, a key lipid mediator involved in numerous diseases and physiological processes. However, clinical trials need to be performed in order to assess the importance of ATX inhibition by THC during medicinal cannabis consumption.
Pharmacokinetics
Absorption
With oral administration of a single dose, THC is almost completely absorbed by the gastrointestinal tract.[16] However, due to first-pass metabolism in the liver and the high lipid solubility of THC, only about 5 to 20% reaches circulation.[26][16] Following oral administration, concentrations of THC and its major active metabolite11-hydroxy-THC (11-OH-THC) peak after 0.5 to 4Template:Nbsphours, with median time to peak of 1.0 to 2.5Template:Nbsphours at different doses.[16][26] In some cases, peak levels may not occur for as long as 6Template:Nbsphours.[26] Concentrations of THC and 11-hydroxy-THC in the circulation are approximately equal with oral administration.[16] There is a slight increase in dose proportionality in terms of peak and area-under-the-curve levels of THC with increasing oral doses over a range of 2.5 to 10Template:Nbspmg.[16] A high-fat meal delays time to peak concentrations of oral THC by 4Template:Nbsphours on average and increases area-under-the-curve exposure by 2.9-fold, but peak concentrations are not significantly altered.[16] A high-fat meal additionally increases absorption of THC via the lymphatic system and allows it to bypass first-pass metabolism.[27] Consequently, a high-fat meal increases levels of 11-hydroxy-THC by only 25% and most of the increase in bioavailability is due to increased levels of THC.[27]
The bioavailability of THC when smoking or inhaling is approximately 25%, with a range of 2% to 56% (although most commonly between 10 and 35%).[17][28][26] The large range and marked variability between individuals is due to variation in factors including product matrix, ignition temperature, and inhalational dynamics (e.g., number, duration, and intervals of inhalations, breath hold time, depth and volume of inhalations, size of inhaled particles, deposition site in the lungs).[17][28] THC is detectable within seconds with inhalation and peak levels of THC occur after 3 to 10Template:Nbspminutes.[26][28] Smoking or inhaling THC results in greater blood levels of THC and its metabolites and a much faster onset of action than oral administration of THC.[17][28] Inhalation of THC bypasses the first-pass metabolism that occurs with oral administration.[17] The bioavailability of THC with inhalation is increased in heavy users.[26]
Transdermal administration of THC is limited by its extreme water insolubility.[17] Efficient skin transport can only be obtained with permeation enhancement.[17] Transdermal administration of THC, as with inhalation, avoids the first-pass metabolism that occurs with oral administration.[17]
More than 55% of THC is excreted in the feces and approximately 20% in the urine. The main metabolite in urine is the ester of glucuronic acid and 11-OH-THC and free THC-COOH. In the feces, mainly 11-OH-THC was detected.[32]
Script error: No such module "Labelled list hatnote".
The preparation of THC was reported in 1965. that procedure called for the intramolecular alkyl lithium attack on a starting carbonyl to form the fused rings, and a tosyl chloride mediated formation of the ether.[38]Template:Third-party inline
Script error: No such module "Labelled list hatnote".
THC and its 11-OH-THC and THC-COOH metabolites can be detected and quantified in blood, urine, hair, oral fluid or sweat using a combination of immunoassay and chromatographic techniques as part of a drug use testing program or in a forensic investigation.[54][55][56] There is ongoing research to create devices capable of detecting THC in breath.[57][58]
Regulation
THC, along with its double bond isomers and their stereoisomers,[59] is one of only three cannabinoids scheduled by the UN Convention on Psychotropic Substances (the other two are dimethylheptylpyran and parahexyl). It was listed under Schedule I in 1971, but reclassified to Schedule II in 1991 following a recommendation from the WHO. Based on subsequent studies, the WHO has recommended the reclassification to the less-stringent Schedule III.[60] Cannabis as a plant is scheduled by the Single Convention on Narcotic Drugs (Schedule I and IV). It is specifically still listed under Schedule I by US federal law[61] under the Controlled Substances Act for having "no accepted medical use" and "lack of accepted safety". However, dronabinol, a pharmaceutical form of THC, has been approved by the FDA as an appetite stimulant for people with AIDS and an antiemetic for people receiving chemotherapy under the trade names Marinol and Syndros.[62]
As of 2023, 38 states, four territories, and the District of Columbia allow medical use of cannabis (in which THC is the primary psychoactive component), with the exception of Georgia, Idaho, Indiana, Iowa, Kansas, Nebraska, North Carolina, South Carolina, Tennessee, Texas, Wisconsin, and Wyoming.[65] As of 2022, the federal government maintains cannabis as a schedule I controlled substance, while dronabinol is classified as Schedule III in capsule form (Marinol) and Schedule II in liquid oral form (Syndros).[66][67]
In Canada
As of October 2018 when recreational use of cannabis was legalized in Canada, some 220 dietary supplements and 19 veterinary health products containing not more than 10 parts per million of THC extract were approved with general health claims for treating minor conditions.[8]
Research
In April 2014, the American Academy of Neurology found evidence supporting the effectiveness of the cannabis extracts in treating certain symptoms of multiple sclerosis and pain, but there was insufficient evidence to determine effectiveness for treating several other neurological diseases.[68] A 2015 review confirmed that medical marijuana was effective for treating spasticity and chronic pain, but caused numerous short-lasting adverse events, such as dizziness.[69]
Multiple sclerosis symptoms
Spasticity. Based on the results of three high-quality trials and five of lower quality, oral cannabis extract was rated as effective, and THC as probably effective, for improving people's subjective experience of spasticity. Oral cannabis extract and THC both were rated as possibly effective for improving objective measures of spasticity.[68][69]
Centrally mediated pain and painful spasms. Based on the results of four high-quality trials and four low-quality trials, oral cannabis extract was rated as effective, and THC as probably effective in treating central pain and painful spasms.[68]
Bladder dysfunction. Based on a single high quality study, oral cannabis extract and THC were rated as probably ineffective for controlling bladder complaints in multiple sclerosis[68]
Neurodegenerative disorders
Huntington disease. No reliable conclusion could be drawn regarding the effectiveness of THC or oral cannabis extract in treating the symptoms of Huntington disease as the available trials were too small to reliably detect any difference[68]
Parkinson's disease. Based on a single study, oral CBD extract was rated probably ineffective in treating levodopa-induced dyskinesia in Parkinson's disease.[68]
Alzheimer's disease. A 2009 Cochrane Review found insufficient evidence to conclude whether cannabis products have any utility in the treatment of Alzheimer's disease.[70]
Other neurological disorders
Tourette syndrome. The available data was determined to be insufficient to allow reliable conclusions to be drawn regarding the effectiveness of oral cannabis extract or THC in controlling tics.[68]
Cervical dystonia. Insufficient data was available to assess the effectiveness of oral cannabis extract of THC in treating cervical dystonia.[68]
Potential for toxicity
Preliminary research indicates that prolonged exposure to high doses of THC may interfere with chromosomal stability, which may be hereditary as a factor affecting cell instability and cancer risk. The carcinogenicity of THC in the studied populations of so-called "heavy users" remains dubious due to various confounding variables, most significantly concurrent tobacco use.[71]
